Медицинская литература. Новинки

 

 

 

 

 

 

ОСОБЕННОСТИ ДИАГНОСТИКИ И ЛЕЧЕНИЯ БОЛЕЗНИ ГРЕЙВСА У ДЕТЕЙ И ПОДРОСТКОВ

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1. Дедов И.И., Мельниченко Г.А. Болезнь Грейвса и эндокринная
офтальмопатия. 2012; 145 с.
2. Брук Чарльз Г.Д., Браун Розалинд С. Руководство по детской
эндокринологии. 2009; 325 с.
3. Ajjan R.A., Kemp E.H., Waterman E.A. et al. Detection of binding
and blocking autoantibodies to the human sodiumiodide sym
porter in patients with autoimmune thyroid disease. J. Clin.
Endocrinol. Metab. 2000; 85: 2020–2027.
4. Ajjan R.A., Weetman A.P. Techniques to quantify TSH receptor
antibodies. Nat. Clin. Pract. Endocrinol. Metab. 2008; 4 (8):
461–468.
5. Allahabadia A., Daykin J., Holder R.L. et al. Age and gender pre
dict the outcome of treatment for Graves' hyperthyroidism. J. Clin.
Endocrinol. Metab. 2000; 85: 1038–1042.
6. Alexander E.K., Larsen P.R. High dose 131I therapy for the treat
ment of hyperthyroidism caused by Graves' disease. J. Clin.
Endocrinol. Metab. 2002; 87: 1073–1077.
7. Andrade V.A., Gross J.L., Maia L. The effect of methimazole pre
treatment on the efficacy of radioactive iodine therapy in Graves'
hyperthyroidism: Oneyear followup of a prospective, randomized study. J. Clin. Endocrinol. Metab. 2001; 86: 3488–3493.
8. ATA Guidelines. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid
Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21: 593–630.
9. Bartalena L., Pinchera A., Marcocci C. Management of Graves'
ophthalmopathy: Reality and perspectives. Endocrine Rev. 2000;
21: 168–199.
10. Bergman P., Auldist A.W., Cameron F. Review of the outcome of
management of Graves’ disease in children and adolescents. J.
Paediatr. Child. Health. 2001; 37 (2): 176–182.
11. Brown R.S. Autoimmune thyroid disease: unlocking a complex
puzzle. Curr. Opin. Pediatr. 2009; 21 (4): 523–528.
12. Brown R.S. Thyroid international Merck KgaA, Darmstadt,
Germany. 2011; 4.
13. Cappelli C., Gandossi E., Castellano M. et al. Prognostic value of
thyrotropin receptor antibodies (TRAb) in Graves’ disease:
a 120 months prospective study. Endocrinol. J. 2007; 54 (5):
713–720.
14. Chazenbalk G.D., McLachlan S.M., Pichurin P. et al. A prionlike
shift between two conformational forms of a recombinant thyrotropin receptor receptor Asubunit module: Purification and stabilization using chemical chaperones of the form reactive with
Graves' autoantibodies. J. Clin. Endocrinol. Metab. 2001; 86:
1287–1293.
15. Cooper D.S. Antithyroid drugs. N. Engl. J. Med. 2005; 352 (9):
905–917.
16. Cooper D.S., Rivkees S.A. Putting propylthiouracil in perspective.
J. Clin. Endocrinol. Metab. 2009; 94: 1881–1882.
17. Feingold S.B., Smith J., Houtz J. et al. Prevalence and functional
significance of thyrotropin receptor blocking antibodies in children
and adolescents with chronic lymphocytic thyroiditis. J. Clin.
Endocrinol. Metab. 2009; 94 (12): 4742–4748.
18. Glaser N.S., Styne D.M. Predicting the likelihood of remission in
children with Graves’ disease: a prospective, multicenter study.
Pediatrics. 2008; 121 (3): 481–488.
19. Hermsen D., Eckstein A., Schinner S. et al. Reproducibility of
Elecsys antiTSHR testresults in a lottolot comparison. Horm.
Metab. Res. 2010; 42 (4): 295–297.
20. Hovens G.C., Buiting A.M., Karperien M. et al. A bioluminescence
assay for thyrotropin receptor antibodies predicts serum thyroid
hormone levels in patients with de novo Graves’ disease. Clin.
Endocrinol. (Oxf.). 2006; 64 (4): 429–435.
21. http://www.thyroidmanager.org/, published by Endocrine
Education, Inc, South Dartmouth, MA, USA.
22. Imrie H., Vaidya B., Perros P. et al. Evidence for a Graves' disease
susceptibility locus at chromosome Xp11 in a United Kingdom
population. J. Clin. Endocrinol. Metab. 2001; 86: 626–630.
23. Kadmon P.M., Noto R.B., Boney C.M. et al. Thyroid storm in
a child following radioactive iodine (RAI) therapy: A consequence
of RAI versus withdrawal of antithyroid medication. J. Clin.
Endocrinol. Metab. 2001; 86: 1865–1867.
24. Kaguelidou F., Alberti C., Castanet M. et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of
antithyroid drug treatment. J. Clin. Endocrinol. Metab. 2008; 93
(10): 3817–3826.
25. Kaguelidou F., Carel J.C., Leger J. Graves disease in childhood:
advances in management with antithyroid drug therapy. Horm.
Res. 2009; 71: 310–317.
26. Kamijo K., Murayama H., Uzu T. et al. A novel bioreporter assay for
thyrotropin receptor antibodies using a chimeric thyrotropin
receptor (mc4) is more useful in differentiation of Graves’ disease
from painless thyroiditis than conventional thyrotropinstimulat
ing antibody assay using porcine thyroid cells. Thyroid. 2010; 20
(8): 851–856.
27. Lytton S.D., Kahaly G.J. Bioassays for TSHreceptor autoantibodies: an update. Autoimmun. Rev. 2010; 10 (2): 116–122.
28. Meller J., Jauho A., Hufner M. et al. Disseminated thyroid autonmy of Graves' disease: Reevaluation by a second generation TSH
receptorantibody assay. Thyroid. 2000; 10: 1085–1091.
29. Metcalfe R., Jordan N., Watson P. et al. Demonstration of
immunoglobulin G, A, and E autoantibodies to the human thyrotropin receptor using flow cytometry. J. Clin. Endocrinol.
Metab. 2002; 87: 1754–1761.
30. Pedersen I.B., Handberg A., Knudsen N. et al. Assays for thyroid
stimulating hormone receptor antibodies employing different ligands and ligand partners may have similar sensitivity and specificity but are not interchangeable. Thyroid. 2010; 20 (2): 127–133.
31. Pichurin P., Pichurina O., Chazenbalk G.D. et al. Immune deviation away from Th1 in interferonγknockout mice does not
enhance TSH receptor antibody production after naked DNA vaccination. Endocrinology. 2002; 143: 1182–1189.
32. Prummel M.F. Recent developments in Graves' ophthalmopathy.
Kluwer Academic Publishers, Boston, USA, 2000.
33. Rahhal S.N., Eugster E.A. Thyroid stimulating immunoglobulin is
often negative in children with Graves’ disease. J. Pediatr.
Endocrinol. Metab. 2008; 21 (11): 1085–1088.
34. Rapoport B., McLachlan S.M. Graves' disease: pathogenesis and
treatment, Kluwer Academic Publishers. Boston, USA, 2000.
35. Rivkees S.A., Dinauer C. An optimal treatment for pediatric
Graves’ disease is radioiodine. J. Clin. Endocrinol. Metab. 2007;
92 (3): 797–800.
36. Rivkees S.A., Sklar C., Freemark M. Clinical review 99: The management of Graves’ disease in children, with special emphasis on
radioiodine treatment. J. Clin. Endocrinol. Metab. 1998; 83 (11):
3767–3776.
37. Rivkees S.A., Stephenson K., Dinauer C. Adverse events associated
with methimazole therapy of graves’ disease in children. Int. J.
Pediatr. Endocrinol. 2010: 176970.
38. Rivkees S.A., Szarfman A. Dissimilar hepatotoxicity profiles of
propylthiouracil and methimazole in children. J. Clin. Endocrinol.
Metab. 2010; 95 (7): 3260–3267.
39. Schwartz K.M., Fatourechi V., Ahmed D.D.F., Pond G.R.
Dermopathy of Graves' disease (pretibial myxedema): Longterm
outcome. J. Clin. Endocrinol. Metab. 2002; 87: 438–446.
40. Sera N., Ashizawa K., Ando T. et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid.
2000; 10: 595–599.
41. Smith J., Brown R.S. Persistence of thyrotropin (TSH) receptor
antibodies in children and adolescents with Graves’ disease treated
using antithyroid medication. Thyroid. 2007; 17 (11): 1103–1107.
42. Smith B.R., Sanders J., Furmaniak J. TSH receptor antibodies.
Thyroid. 2007; 17 (10): 923–938.
43. Sherman J., Thompson G.B., Lteif A. et al. Surgical management of
Graves disease in childhood and adolescence: an institutional
experience. Surgery. 2006; 140 (6): 1056–1061.
44. Werga'Kjellman P., Zedenius J., Tallstedt L. et al. Surgical treatment of hyperthyroidism: A tenyear experience. Thyroid. 2001;
11: 187–192.
45. Xiao H., Zhuang W., Wang S. et al. Arterial embolization: A novel
approach to thyroid ablative therapy for Graves' disease. J. Clin.
Endocrinol. Metab. 2002; 87: 3583–3589.
46. Zophel K., Roggenbuck D., Wunderlich G., Schott M. Continuously
increasing sensitivity over three generations of TSH receptor
autoantibody assays. Horm. Metab. Res. 2010; 42 (12): 900–902.

Management of Graves' disease in children and adolescents

Keywords: